Ginkgolic Acid C15:1
(Synonyms: 银杏酸; Ginkgolic acid (15) 目录号 : GC10134
An inhibitor of SUMOylation
Cas No.:22910-60-7
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Ginkgolic acid is an alkylphenol derivative that causes allergic skin inflammation. IC50 values of ginkgolic acid against the SUMOylation of RanGAP1-C2 are 3.0 μM. Ginkgolic Acid, a Major Component of Ginkgo biloba Extract, inhibited SUMOylation in vitro and in vivo [1].
The cytotoxicity of ginkgolic acid (15:1) in primary rat hepatocytes was lower than in HepG2 cells. Ginkgolic acid (15:1) was demonstrated less cytotoxicity in four-day-cultured primary rat hepatocytes than in 20-h cultured ones. Co-incubation with selective CYP inhibitors, α-naphthoflavone and ketoconazole, could decrease the cytotoxicity of ginkgolic acid (15:1) in primary rat hepatocytes. In agreement, pretreatment with selective CYP inducers, β-naphthoflavone and rifampin, could increase the cytotoxicity of ginkgolic acid (15:1) in HepG2 cells [2]. Ginkgolic acid inhibited the growth of tumorogenic cell lines in a dose- and time-dependent manner. Tumor cells were treated with GA for 72 h, 70.53 ± 4.54% Hep-2 and 63.5 ± 7.2% Tca8113 cells were retarded at GO/G1 phase, and the percentage of apoptosis was 40.4 ± 1.58 and 38.4 ± 1.7%, respectively [3]. In 293T cells expressing Flag-tagged SUMO, ginkgolic Acid Inhibited SUMOylation. Ginkgolic acid impaired SUMOylation by blocking the formation of an E1-SUMO thioester complex, by directly binding to E1 [1].
References:
[1] Fukuda I, Ito A, Hirai G, et al. Ginkgolic acid inhibits protein SUMOylation by blocking formation of the E1-SUMO intermediate[J]. Chemistry & biology, 2009, 16(2): 133-140.
[2] Liu Z H, Zeng S. Cytotoxicity of ginkgolic acid in HepG2 cells and primary rat hepatocytes[J]. Toxicology letters, 2009, 187(3): 131-136.
[3] Zhou C, Li X, Du W, et al. Antitumor effects of ginkgolic acid in human cancer cell occur via cell cycle arrest and decrease the Bcl-2/Bax ratio to induce apoptosis[J]. Chemotherapy, 2010, 56(5): 393-402.
|
Cell experiment: |
Jurkat cells (106 cells/mL) are cultured in the RPMI medium with or without different concentrations of ginkgolic acid for 48 hours to test the cytotoxicity of ginkgolic acid. The cytotoxicity of ginkgolic acid is determined using a tetrazolium compound (MTS) and an electron coupling reagent (PMS). MTS is chemically reduced by cells into formazan, which is soluble in the tissue culture medium. The measurement of the absorbance of the formazan can be carried out using 96 well microplates at 492 nm. Since the production of formazan is proportional to the number of living cells, the intensity of the produced color is a good indication of the viability of the cells. |
|
References: [1]. Fukuda I, et al. Ginkgolic acid inhibits protein SUMOylation by blocking formation of the E1-SUMO intermediate. Chem Biol. 2009 Feb 27;16(2):133-40. |
|
| Cas No. | 22910-60-7 | SDF | |
| 别名 | 银杏酸; Ginkgolic acid (15 | ||
| 化学名 | 2-hydroxy-6-(8Z)-8-pentadecenyl-benzoic acid | ||
| Canonical SMILES | OC1=CC=CC(CCCCCCC/C=C\CCCCCC)=C1C(O)=O | ||
| 分子式 | C22H34O3 | 分子量 | 346.5 |
| 溶解度 | ≤50mg/ml in ethanol;30mg/ml in DMSO;50mg/ml in dimethyl formamide | 储存条件 | Store at -20°C,protect from light |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 2.886 mL | 14.43 mL | 28.86 mL |
| 5 mM | 0.5772 mL | 2.886 mL | 5.772 mL |
| 10 mM | 0.2886 mL | 1.443 mL | 2.886 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet